Definium’s dissolving LSD tablet beat placebo in a large trial for generalized anxiety disorder, with effects seen within days — sending its shares up.
With more than 2,000 dead in what may become the second-largest Ebola epidemic ever, WHO is moving to test Merck’s Ervebo vaccine in a Phase 3 trial in Congo.
Retatrutide isn’t approved anywhere — but a gray market of compounders and ‘peptide’ sellers is already hawking copies, prompting Lilly to go to court.
Co-founded by Georg Schett — who showed CAR-T can drive lupus into remission — the Deerfield-backed startup aims to reset the immune system with more convenient antibodies.
Beyond hunger, drugs like Ozempic appear to dial down urges for alcohol, nicotine and more — and researchers point to a reward hub called the lateral septum.
A French randomized trial found healthy, low-risk people over 75 who stopped their preventive statins were no worse off on death or heart events over three years — with big caveats.
In lab-infected human immune cells, dexamethasone dialed down damaging inflammation from a stubborn lung infection while still letting the cells fight the bacteria.
The nationwide recall covers one lot of Tyenne (tocilizumab-aazg) injection after glass particles were found in the vials, a risk of irritation or vein inflammation.
K2 Therapeutics, a Flagship-style ‘hub-and-spoke’ biotech that in-licenses drug candidates worldwide, named the former Legend Biotech chief as its new leader.
BeOne gains Asian rights to Revolution’s RAS(ON) inhibitors and will test them with its own oncology drugs against some of cancer’s hardest targets.
Structure Therapeutics’ once-daily oral drug aleniglipron cut body weight by 12.1% over 36 weeks — a convenient, needle-free take on the blockbuster GLP-1 class.
Sobi gains commercial rights to lacutamab, a first-in-class antibody for cutaneous T-cell lymphoma now in a Phase 3 confirmatory trial and heading for accelerated approval.